Where do NewAmsterdam Pharma Company's ratios come from?

Every ratio is computed from NewAmsterdam Pharma Company's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Profitability
Operating margin	-953.6%+49.3pp	-1,002.9%-427pp	-575.8%-306pp	-270%+133pp	-402.5%-15.6pp
Net margin	-942.8%-37.0pp	-905.7%-278pp	-627.3%-368pp	-258.9%+139pp	-397.5%+133pp
EBITDA margin	-952.6%+49.4pp	-1,001.9%-427pp	-575.2%-306pp	-269.7%+132pp	-402.2%-15.5pp
Free cash flow margin	-630.1%+27.7pp	-657.8%-248pp	-410.1%-216pp	-194.2%+104pp	-298.5%+50.9pp
Returns
Return on equity	-29.5%-1.2pp	-28.3%+11.7pp	-39.9%-11.5pp	-28.4%+3.1pp	-31.5%+14.7pp
Return on assets	-27.4%-2.5pp	-24.9%+11.1pp	-36.1%—	——	——
Efficiency
Asset turnover	0×0.0×	0×0.0×	0.1×—	——	——
Liquidity
Current ratio	9.8×+1.9×	7.9×-4.7×	12.6×-8.5×	21.1×+1.1×	20×+11.9×
Quick ratio	9.8×+1.9×	7.9×-4.7×	12.6×-8.5×	21.1×+1.1×	20×+11.9×
Cash ratio	6.8×+1.1×	5.7×-3.5×	9.2×-6.2×	15.4×-2.8×	18.3×+11.1×
Leverage
Debt-to-equity	0×0.0×	0×0.0×	0×0.0×	0×0.0×	0×0.0×
Debt-to-assets	0×0.0×	0×0.0×	0×0.0×	0×0.0×	0×0.0×
Valuation
Market capitalization	$3.68B-7.5%	$3.98B+24.2%	$3.2B+55.1%	$2.07B-8.1%	$2.25B-18.3%
Enterprise value	$3.22B-7.6%	$3.49B+30.9%	$2.67B+77.4%	$1.5B+0.2%	$1.5B-24.2%
Price / sales	163.1×-13.7×	176.8×+85.9×	90.9×+58.6×	32.3×-15.4×	47.7×-12.7×
Price / book	5.5×-0.3×	5.8×+1.4×	4.4×+1.7×	2.7×-0.2×	2.9×-0.7×
EV / sales	142.8×-12.2×	155×+79.4×	75.6×+52.1×	23.5×-8.3×	31.8×-11.6×
Free cash flow yield	-3.9%-0.1pp	-3.7%+0.8pp	-4.5%+1.5pp	-6%+0.2pp	-6.3%-0.5pp
Earnings yield	-5.8%-0.7pp	-5.1%+1.8pp	-6.9%+1.1pp	-8%+0.3pp	-8.3%+0.4pp

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where do NewAmsterdam Pharma Company's ratios come from?: Every ratio is computed from NewAmsterdam Pharma Company's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.